Jan 26, 2023 · Washington, D.C. – U.S. Senator Elizabeth Warren (D-Mass.) sent a letter to Federal Trade Commission (FTC) Chair Lina Khan and FTC Commissioners Alvardo Bedoya and Rebecca Kelly Slaughter urging the agency to closely scrutinize two pending big pharmaceutical mergers: Amgen and Horizon Therapeutics, and Indivior and Opiant.

Nov 9, 2023 · In the letter, the Senator underscores FTC’s responsibility to hold Big Pharma accountable and protect competition and access to pharmaceutical products, given concerns that deals such as this one could raise the price of medicine.

Oct 10, 2024 · Washington, DC – U.S. Senator Elizabeth Warren (D-Mass.) sent a letter to Federal Trade Commission (FTC) Chair Lina Khan, urging the FTC to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, and block the deal if it is found to be illegal under antitrust law.

Oct 29, 2024 · Sen. Elizabeth Warren (D-Mass.) is urging the Federal Trade Commission to scrutinize recent deals from McKesson and Cardinal Health to buy oncology practices, saying those transactions pose...

Jan 26, 2023 · Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals.

4 days ago · US Senator Elizabeth Warren has asked the Federal Trade Commission (FTC) to look into a $16.5 billion deal that would give Novo Nordisk control of manufacturing facilities currently...

Apr 15, 2024 · Senator Elizabeth Warren (D-MA) has written a letter to the Federal Trade Commission, saying that TurboTax “continues to relentlessly upsell” customers while also directing them away from...

Oct 10, 2024 · U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading...

Aug 1, 2024 · Sen. Elizabeth Warren (D-Mass.) voiced her support for the Federal Trade Commission's ban on noncompete agreements and said she believes ongoing legal efforts to roll back the rule are wrong. The ban, which is set to take effect Sept. 4, has so far faced legal challenges in Texas and Pennsylvania.

Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's planned $16.5 billion acquisition of Catalent (NYSE:CTLT).